Free shipping on all orders over $ 500


Cat. No. M2180
SGI-7079 Structure
Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 95 In stock
10mg USD 150 In stock
50mg USD 560 In stock
100mg USD 730 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

SGI-7079 is a novel Axl inhibitor. SGI-7079 decreased IBC cell proliferation, migration and invasion in vitro and inhibited tumor growth of IBC cells in vivo. Mesenchymal cells also expressed increased levels of the receptor tyrosine kinase Axl and showed a trend toward greater sensitivity to the Axl inhibitor SGI-7079, whereas the combination of SGI-7079 with erlotinib reversed erlotinib resistance in mesenchymal lines expressing Axl and in a xenograft model of mesenchymal NSCLC.

Customer Product Validations & Biological Datas
Source Cancer Res (2013). Figure 6. SGI-7079
Method MTT
Cell Lines SUM149 cells
Concentrations 1 mmol/L
Incubation Time 72 h
Results SGI-7079 treatment inhibited the phosphorylation of Axl at Tyr 702 upon Gas6 stimulation in SUM149 cells
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 455.53
Formula C26H26FN7
CAS Number 1239875-86-5
Purity >99%
Solubility 91 mg/mL in DMSO
Storage at -20°C

TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase.
Wang X, et al. Cancer Res. 2013 Sep 6. PMID: 24014597.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA, et al. Clin Cancer Res. 2013 Jan 1;19(1):279-90. PMID: 23091115.

Related Axl Products

TP-0903 is a potent and selective AXL inhibitor with an IC50 value of 27 nM.


R428 is a potent and selective small-molecule inhibitor of Axl kinase with IC50 of 14 nM.

Abmole Inhibitor Catalog 2017

Keywords: SGI-7079 supplier, Axl, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.